Startups·29 May 2026·via Pr Newswire Apac
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
BOSTON , May 29, 2026 /PRNewswire/ -- XtalPi (2228. HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc.
#xtalpi#dovetree medicines unus inc.#ind-enabling studies#advances#dynamic conformation precision modeling platform#strategic collaboration#receives#surerxn reaction prediction model
Original reporting by Pr Newswire ApacWe don't republish, read the full story →
Related reading
6 stories
🇮🇳·Startups
VC Firm Activate Closes $105 Million AI Fund to Back India’s Next Wave of AI Startups
🇸🇬·Startups
UBS may be cutting costs, but if you're a US banker who's worked for Credit Suisse it's hiring
🇵🇭·Startups
DICT budget deferred over unresolved child safety issues with Facebook
🇲🇾·Startups
HK’s DC ambitions face US$2.6bil funding test
🇲🇾·Startups
Auto industry finally moves to tackle glut
🇮🇳·Startups